3. RESULTS
As shown in Fig.1 (PRISMA flow chart), summarizes the selection
of studies. A total of 3063 citations were identified from databases,
including PubMed, Web of Science and Embase, there were 1652 duplicates.
After screening the title and abstract, 1241 citations were removed.
Full-text copies of twelve articles could not be achieved and 158
full-text studies were finally reviewed. 113 studies excluded due to no
safety index. Detailed exclusion reasons for other studies are shown in
figuer1. Eventually, 28 studies were included in the final
meta-analysis. Studies characteristics of the selected are shown inTable 1 [12-14, 16-40].
Of the 28 articles included in the final analysis, 31cohort,129980
patients notified total adverse events after COVID-19 vaccination in
patients with ANC. The diseases included were: MS (17/31, 54.8%), MG
(10/31, 32.3%), and NMOSD (4/31, 12.9%). studies reported the
incidence of adverse reactions after the first, second, and third dose
vaccination was 20(71.4%),17(60.7%),6(21.4%)respectively. For
different vaccine types, mRNA vaccines (either Pfizer-BioNTech or
Moderna) accounted for 46.4%, inactivated vaccines (CoronaVac, Sinovac)
accounted for 14.3%, and mixed vaccination types accounted for 39.3%.